Literature DB >> 15917113

A recombinant envelope protein vaccine against West Nile virus.

Michel Ledizet1, Kalipada Kar, Harald G Foellmer, Tian Wang, Sandra L Bushmich, John F Anderson, Erol Fikrig, Raymond A Koski.   

Abstract

West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge with a lethal viral dose. Sera from immunized horses, administered to naive mice, conferred resistance against a lethal WN viral challenge. In addition, sera of immunized horses neutralized West Nile virus in vitro, as demonstrated by plaque reduction assays. This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917113     DOI: 10.1016/j.vaccine.2005.03.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

Review 2.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 3.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Inhibition of neutrophil function by two tick salivary proteins.

Authors:  Xiuyang Guo; Carmen J Booth; Michael A Paley; Xiaomei Wang; Kathleen DePonte; Erol Fikrig; Sukanya Narasimhan; Ruth R Montgomery
Journal:  Infect Immun       Date:  2009-03-30       Impact factor: 3.441

5.  Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.

Authors:  Michael M Lieberman; David E Clements; Steven Ogata; Gordon Wang; Gloria Corpuz; Teri Wong; Tim Martyak; Lynne Gilson; Beth-Ann Coller; Julia Leung; Douglas M Watts; Robert B Tesh; Marina Siirin; Amelia Travassos da Rosa; Tom Humphreys; Carolyn Weeks-Levy
Journal:  Vaccine       Date:  2006-08-30       Impact factor: 3.641

6.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells.

Authors:  Subhabrata Biswas; Hong Chang; Phuong T N Sarkis; Erol Fikrig; Quan Zhu; Wayne A Marasco
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

8.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

10.  Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Authors:  Ana P Goncalvez; Cheng-Hsin Chien; Kamolchanok Tubthong; Inna Gorshkova; Carrie Roll; Olivia Donau; Peter Schuck; Sutee Yoksan; Sy-Dar Wang; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.